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A B S T R A C T   
Vaccine hesitancy could undermine efforts to control COVID-19. We investigated the prevalence of COVID-19 
vaccine hesitancy in the UK and identified vaccine hesitant subgroups. The ‘Understanding Society’ COVID-19 
survey asked participants (n = 12,035) their likelihood of vaccine uptake and reason for hesitancy. Cross- 
sectional analysis assessed vaccine hesitancy prevalence and logistic regression calculated odds ratios. Overall 
vaccine hesitancy was low (18% unlikely/very unlikely). Vaccine hesitancy was higher in women (21.0% vs 
14.7%), younger age groups (26.5% in 16–24 year olds vs 4.5% in 75 + ) and those with lower education levels 
(18.6% no qualifications vs 13.2% degree qualified). Vaccine hesitancy was high in Black (71.8%) and Pakistani/ 
Bangladeshi (42.3%) ethnic groups. Odds ratios for vaccine hesitancy were 13.42 (95% CI:6.86, 26.24) in Black 
and 2.54 (95% CI:1.19, 5.44) in Pakistani/Bangladeshi groups (compared to White British/Irish) and 3.54 (95% 
CI:2.06, 6.09) for people with no qualifications versus degree. Urgent action to address hesitancy is needed for 
some but not all ethnic minority groups.   
1. Introduction 
Vaccines and immunisation programmes save lives. The World 
Health Organisation (WHO) estimates that immunisation programmes 
across the world prevent 2–3 million deaths every year and are not only 
cost effective but a key element of preventative healthcare (WHO, 
2020). Since the emergence of the Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) in 2019, the global pandemic has resulted 
in over 72 million confirmed cases and 1.6 million deaths in 220 
countries worldwide (as at 18 Dec 2020) (WHO, 2020). An effective and 
safe vaccine is vital to controlling the COVID-19 outbreak. However, not 
only does a vaccine need to be safe and effective, it must also be taken up 
by those people at greatest risk of harm from the disease. Ideally, uptake 
by a large enough proportion of the population will offer protection to 
people who remain unimmunised, referred to as achieving ‘herd im-
munity’. For COVID-19, vaccine uptake would need to be between 
approximately 67% and 80% to reduce spread of the disease (Randolph 
and Barreiro, 2020; Mills et al., 2020). Understanding who will take up a 
vaccine, who plans not to or are uncertain, and why, is critical to 
designing a successful vaccination programme. 
Even before the emergence of SARS-CoV-2, WHO had already 
highlighted vaccine hesitancy as one of the ten leading threats to global 
health (WHO, 2019). The WHO Strategic Advisory Group of Experts 
Working Group on Vaccine Hesitancy define it as the “delay in acceptance 
or refusal of safe vaccines despite availability of vaccination services” 
(MacDonald, 2015). Reasons for vaccine hesitancy are acknowledged as 
being complex but also context specific. Hesitancy around uptake can 
vary geographically, at different times and for different vaccines by a 
range of factors including complacency around the disease, convenience 
of access and confidence in the vaccine itself. For example, in the H1N1 
pandemic of 2009, there was a perception that the vaccine was rushed 
and unsafe (Schoch-Spana et al., 2020). Similar concerns have been 
raised about the speed of COVID-19 vaccine development (Mills et al., 
2020). Studies into potential COVID-19 vaccination, based on non- 
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representative samples, have indicated that vaccine hesitancy associated 
with age, gender, income, education level and ethnicity will be an issue 
(Ipsos, 2020; Murphy et al., 2021; Paul et al., 2021; Williams et al., 
2021). In studies conducted prior to vaccine approval, hesitancy rates 
for a COVID-19 vaccine in the general UK population varied greatly, 
from approximately 12% (Freeman et al., 2020) to 31%. (Murphy et al., 
2021) In studies where ethnicity was considered, small sample sizes did 
not allow for detailed analysis of specific ethnic groups, but suggested 
greater hesitancy amongst people classified as non-White (Murphy et al., 
2021; Paul et al., 2021; Williams et al., 2021; Freeman et al., 2020). This 
is particularly important, given the often greater risk of COVID-19 harms 
observed among several ethnic minority groups (Lassale et al., 2020; 
Niedzwiedz et al., 2020; Williamson et al., 2020). 
The COVID-19 pandemic has been described as a ‘syndemic’ where it 
not only acts together with, but worsens and amplifies, non- 
communicable diseases and social conditions and hence exacerbates 
inequalities in health (Bambra et al., 2020). As inequalities already exist 
in seasonal influenza and pneumococcal vaccine uptake, with lower 
uptake in more deprived areas (Mangtani et al., 2005; Jain et al., 2017), 
there is reason to believe that inequalities will exist in vaccine uptake 
against COVID-19. Understanding if some subgroups of the population 
are more likely to be vaccine hesitant will help in the formulation of 
vaccination programme strategies to ensure adequate population 
coverage to achieve herd immunity and minimise health inequalities. 
This will be particularly important if greater vaccine hesitancy is found 
among groups at greater risk from COVID-19. We therefore aimed to 
describe how willing the UK population is to be vaccinated against 
COVID-19, to identify which population subgroups are more likely to be 
vaccine hesitant, which are more likely to take up a vaccine, and 




The UK Household Longitudinal Study, also referred to as ‘Under-
standing Society’, is a nationally representative panel study, based on a 
clustered-stratified probability sample of UK households, with boost 
samples of key ethnic minority groups. Sample members living in the UK 
have been interviewed annually since 2009 (Institute for Social and 
Economic Research, 2020). In 2020, during the COVID-19 pandemic, 
participants aged 16+ years who had lived in households that had 
completed at least one of the last two waves of the main Understanding 
Society survey were invited to take part in the COVID-19 survey either 
online or by telephone (n = 42,330). Web surveys took place monthly 
from April to July, then every two months (Institute for Social and 
Economic Research, 2020). For wave 6, carried out from 24th November 
to 1st December 2020, only sample members who had completed at least 
one partial interview in any of the preceding five COVID-19 web sur-
veys, and had not become ineligible through death or moving abroad 
nor opted out of the study, were invited to take part. This resulted in 
19,289 invitations being issued, and 12,035 took part, a response rate of 
62% (University of Essex, 2020). Data for age, sex, ethnicity, education 
level and country of birth were derived from previous waves of the main 
study (Institute for Social and Economic Research, 2020). 
Ethics approval was granted by the University of Essex Ethics Com-
mittee for the COVID-19 surveys (ETH1920-1271). No additional ethical 
approval was necessary for this secondary data analysis. 
2.2. Outcome measures 
Our primary outcome was vaccine hesitancy, assessed by asking all 
participants “Imagine that a vaccine against COVID-19 was available for 
anyone who wanted it. How likely or unlikely would you be to take the 
vaccine?” Possible responses were “Very likely”, “Likely”, “Unlikely” 
and “Very unlikely”. This was collapsed into a binary variable for 
modelling, comparing ‘unlikely and very unlikely’, classified as vaccine 
hesitant, to ‘likely or very likely’. If a participant tried to bypass the 
question, they were given the option of ‘don’t know’ (n = 45) and, given 
the size of the group they were coded as missing. 
Secondary outcomes included reasons for vaccine hesitancy. Vaccine 
hesitant participants were asked “What is the main reason you would not 
take the vaccine?” and asked to pick one main reason from a list of 12 
possible answers (Fig. 3). Participants who were not vaccine hesitant 
were asked “What would be your main reason for taking the vaccine?” and 
asked to choose one main reason from a list of 11 possible answers 
(Fig. 3). All participants were then asked “Which three of these things 
would most increase the chances of you choosing to get vaccinated?” and 
given a list of 9 possible answers (Fig. 3). For the purpose of this analysis, 
we identified if the item was mentioned as any of the three options. 
2.3. Covariates 
Covariates are all taken from the longitudinal mainstage data files. 
Statistical models included age, coded in 5-year age bands to allow for 
non-linearity in the relationship, and gender coded as male/female. 
Ethnicity was self-reported and coded as White British or Irish; Other 
White; three Asian and Asian British groups: Indian, Pakistani/Bangla-
deshi, or Other Asian (includes participants of Chinese ethnicity); Black 
or Black British; and Other. The ethnicity groupings were chosen to 
allow analysis of as detailed ethnic groupings as possible, subject to 
having an adequate sample size for meaningful analysis in each cate-
gory. Country of birth (UK/Not UK) and UK country of residence (En-
gland/Scotland/Wales/Northern Ireland) were also investigated. 
Education level was based on the highest qualification reported in the 
most recent wave (data collected in 2019) and coded as Degree & Other 
Higher Degree, A-Level or equivalent, GCSE or equivalent, other quali-
fication and none. NHS Shielding category (Yes/No) was ascertained 
from previous COVID-19 survey waves on the basis of self-report (“Have 
you received a letter, text or email from the NHS or Chief Medical Officer 
saying that you have been identified as someone at risk of severe illness if you 
catch coronavirus, because you have an underlying disease or health 
condition?”). 
2.4. Statistical analysis 
Descriptive statistics (percentages and 95% confidence intervals 
(CI)) for the outcomes were calculated using cross-sectional weights to 
make the sample representative of the UK community dwelling popu-
lation. Weights were calculated for each COVID-web survey based on 
differential non-response from wave 9. Predictors included in the 
weights were basic demographic factors, household composition, pre-
vious survey outcomes, COVID-19 survey paradata, such as the number 
of reminders issued, economic and health variables. The final weights 
are calculated as the inverse of the response propensity. (Institute for 
Social and Economic Research, 2020) Weights are not calculated for the 
1,974 participants who did not take part at Wave 9, and hence they are 
excluded from the weighted analyses, hence the weighted sample is 
9,981. 
Logistic regression was used because the dependent variable was 
binary. Three models were considered: model 0 - univariate models for 
each covariate, model 1 – statistical analysis including age and gender, 
model 2 – statistical analysis including all covariates. 
Data were cleaned using SPSS version 25 and analysed in R version 
3.6.3 (R Core Team, 2018) using the complex samples method to take 
account of the clustered and stratified sample (Lumley, 2020). Missing 
data were excluded from the analyses using listwise deletion so each 
model may contain different numbers of participants. 
Data Availability 
Understanding Society data are available through the UK Data Ser-
vice. COVID-19 Survey is available here https://beta.ukdataservice.ac. 
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uk/datacatalogue/studies/study?id=8644, and the mainstage here htt 
ps://beta.ukdataservice.ac.uk/datacatalogue/studies/study?id=6614. 
Researchers who would like to use Understanding Society need to reg-
ister with the UK Data Service before being allowed to apply for or 
download datasets. 
Code availability 
This project has employed statistical analytical techniques standard 
in all statistical packages. 
3. Results 
3.1. Sample statistics 
12,035 participants completed the Covid-19 wave 6 survey online 
and the weighted sample is 9,981 (Fig. 1). However, in the weighted 
sample 56 participants did not answer the vaccine hesitancy question 
and 591 participants had missing data on at least one covariate, and 
hence the weighted analytical sample for the full multivariable models is 
9,390, although in other models it varies based on the covariates 
included. The weighted study sample is described in Table 1. 
3.2. Prevalence of vaccine hesitancy 
Overall, intention to have the COVID-19 vaccine was high, 53.5% of 
participants were very likely and a further 28.5% were likely to be 
vaccinated with 18% being vaccine hesitant (reporting unlikely or very 
unlikely). However, there was marked variation in population sub-
groups (Fig. 2). A higher proportion of female participants indicated 
vaccine hesitancy, 21.0% compared to 14.7% of male participants. 
Younger age groups were also more vaccine hesitant with 28.3% of 
younger adults aged 25–34 vaccine hesitant compared to only 14.3% in 
the 55–64 age group, 8.1% in the 65–74 age group and 4.5% in the 75 +
age group. 
Black or Black British were the ethnic group with the highest rate of 
vaccine hesitancy at 71.8%. Pakistani/Bangladeshi groups were the next 
most hesitant ethnic group with 42.3% vaccine hesitant, followed by 
those of Mixed ethnicity (32.4%). The ethnic groups with the highest 
intention to vaccinate were the White British or Irish groups (84.8% 
being likely/very likely to take a vaccine) and the any other Asian 
background group (86.1%; this group includes participants of Chinese 
ethnicity). 
Vaccine hesitancy varied with education level. Vaccine hesitancy 
was lowest in those with degrees (13.2%) and highest in those with 
Fig. 1. Selection of analytical sample.  
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GCSE level education (24.6%). 
3.3. Reasons for vaccine hesitancy 
The main reasons for vaccine hesitancy were concerns over future 
unknown effects of a vaccine, with 42.7% citing this as their main reason 
(Fig. 3). The main reasons for being willing to take up a vaccine were to 
avoid catching COVID-19 or becoming ill from the disease (54.6%) and 
to allow social and family life to get back to normal (12.5%). 
Stated reasons for vaccine hesitancy were often similar across ethnic 
groups (Appendix 1). However, when compared to the White British or 
Irish group, Black or Black British participants were more likely to state 
they ‘Don’t trust vaccines’ (29.2% vs 5.7%) and the Pakistani or Ban-
gladeshi ethnic group cited worries about side-effects (35.4% vs 8.6%) 
more commonly. Women were more likely than men to state that their 
main reason for vaccine hesitancy was concern about side effects and to 
state that they do not trust vaccines. 
A majority of participants (67.8%) reported that knowing a vaccine 
reduced their risk of catching COVID-19 was a factor that would increase 
their chance of taking a vaccine (Fig. 3). Other factors commonly 
identified by participants as increasing their chances of taking a vaccine 
were if it reduced the risk of being seriously ill if they did catch COVID- 
19 (63.7%) and a vaccine being demonstrated to be safe (59.8%). 
When asked what would most convince participants to take the 
vaccine, 43.2% of Black or Black British maintained that they would not 
take it, while a further 44.7% reported that they would if the vaccine 
was demonstrated to be safe. Pakistani/Bangladeshi participants re-
ported that they may be persuaded if the vaccine reduced their risk of 
catching COVID-19 (65.2%) and/or if it was demonstrated to be safe 
(64.6%). 
Females had higher odds of vaccine hesitancy than males (OR 1.55, 
95% CI:1.28, 1.86) and this was still present in model 1 (OR 1.54, 95% 
CI:1.28, 1.86) (Table 2). The risk of being vaccine hesitant was inversely 
related to age with younger age groups having higher odds of vaccine 
hesitancy; the odds in the 16–24 year old category were 1.48 (95% 
CI:1.00, 2.20) compared to those aged 45–54 years. However, once 
adjusting for other covariates this was reduced to 1.29 (95% CI: 0.85, 
1.95). The vaccine hesitancy risk was higher in the 25–34 (OR 1.64, 95% 
CI: 1.16, 2.32) and 35–44 (OR 1.42, 95% CI:1.06, 1.89) than 45–54 year 
olds, and this was present in all models. Conversely those in older age 
groups were less likely to be vaccine hesitant across all models, 55–64 
(OR 0.61, (95% CI:0.46, 0.80), 65–74 (OR 0.33, 95% CI:0.23, 0.46) and 
75+ (OR 0.17, 95% CI:0.08, 0.35). For those participants who had 
received a letter about shielding, the odds of vaccine hesitancy were not 
different to those who are not shielding but were imprecisely estimated, 
and this was true across all models (OR 1.08, 95% CI:0.67, 1.74). 
Higher vaccine hesitancy was seen in most minority ethnic groups 
compared to the White British or Irish group. The highest odds were seen 
in the Black or Black British group (OR 13.42, 95% CI:6.86, 26.24) and 
the Pakistani or Bangladeshi groups (OR 2.54, 95% CI:1.19, 5.44), and 
adjustment for covariates made relatively little difference to these as-
sociations. Participants who were not born in the UK did not have 
greater odds of vaccine hesitancy (OR 0.99 95% CI: 0.67, 1.48) in model 
2. Furthermore, in model 2, there were no substantive differences in 
vaccine hesitancy by country of residence. 
The risk of vaccine hesitancy was inversely related to education in 
model 2. Compared to those with degree-level education there were 
raised odds of vaccine hesitancy among those with A-Level or equivalent 
qualifications (OR 1.48, 95% CI:1.13, 1.95), GCSE or equivalent (OR 
2.52, 95% CI:1.92, 3.31), and no educational qualifications (OR 3.54, 
95% CI:2.06, 6.09), indicating a socioeconomic gradient in vaccine 
hesitancy. 
4. Discussion 
The vast majority (82%) of UK adults are willing to take up a COVID- 
19 vaccine if offered with 18% being vaccine hesitant however marked 
differences exist across population subgroups. Older age and being male 
are strongest drivers of the risk of COVID-19 death, they are less likely to 
be vaccine hesitant, suggesting the vaccination programme could yield 
large health benefits within the UK. Very large differences in vaccine 
hesitancy exist by ethnicity, with Black or Black British and Pakistani or 
Bangladeshi ethnic groups being most hesitant. However, not all mi-
nority ethnic groups had higher vaccine hesitancy, highlighting the 
importance of understanding heterogeneity between minority ethnic 
groups. Overall, the main reasons given for vaccine hesitancy were fears 
around side effects and future adverse effects of a COVID-19 vaccine. 
The main reasons for intended vaccine uptake relate to the avoidance of 
catching the virus or becoming very ill from it, but also to allow social 
and family life to return to normal. Vaccine efficacy and safety were 
identified as factors that would encourage vaccine uptake. 
Our study has several strengths. To our knowledge, it is the first large 
representative study in the UK to survey participants on likely vaccine 
uptake or hesitancy and the reasons why a COVID-19 vaccine would be 
accepted or refused. It also did so at a time when new vaccine devel-
opment and vaccine efficacy was highly reported in the media (end 
Table 1 
Description of the study population.   
Weighted n (%) 
Likelihood of taking up a coronavirus vaccination  
Very likely 5306 (53.2%) 
Likely 2832 (28.4%) 
Unlikely 1131 (11.3%) 
Very unlikely 656(6.6%) 
Missing (including refusal and don’t know) 56 (0.5%) 
Gender  
Male 4666 (46.8%) 
Female 5290 (53.0%) 
Prefer not to say 25 (0.3%) 
Age  
16–24 920 (9.2%) 
25–34 1382(13.8%) 
35–44 1543 (15.5%) 
45–54 1784 (17.9%) 
55–64 1938 (19.4%) 
65–74 1532 (15.3%) 
75+ 882 (8.8%) 
Ethnicity  
White British or Irish 8713 (87.3%) 
Other white background 269 (2.7%) 
Mixed 168 (1.7%) 
Asian or Asian British – Indian 176 (1.8%) 
Asian or Asian British – Pakistani/Bangladeshi 198 (2.0%) 
Asian or Asian British – any other group 106 (1.1%) 
Black or Black British 190 (1.9%) 
Other Ethnic Group 59 (0.6%) 
Missing 102 (1.0%) 
Born in UK  
Born in UK 8991 (90.1%) 
Not Born in UK 824 (8.3%) 
Missing 166 (1.7%) 
UK Country  
England 8424 (84.4%) 
Wales 507 (5.1%) 
Scotland 775 (7.8%) 
Northern Ireland 275 (2.8%) 
Highest Education Level  
Degree & Other Degree 4086 (40.9%) 
A Level or equivalent 2202 (22.1%) 
GCSE or equivalent 2010 (20.1%) 
Other Qualification 846 (8.5%) 
No Qualification 501 (5.0%) 
Missing(no education data in 2019 datafile (wave 10/11) 336 (3.4%) 
NHS Shielding Category  
Yes 721 (7.2%) 
No 9244 (92.6%) 
Don’t know 16 (0.2%) 
Unweighted N = 11,955, weighted N = 9,981. 
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November 2020, but just before the first vaccine was approved on 2nd 
December 2020). The four countries of the UK are now rolling out a 
vaccination programme commencing with those most at risk of mor-
tality from COVID-19. The findings reported here, provide evidence on 
the groups who need targeting and arguments that may be most 
persuasive for them. 
There are also weaknesses of our study which should be noted. The 
survey is web-based so non-participation may have introduced bias into 
the results. However, and following recommended practice for this 
dataset, the results were weighted to account for non-response and 
attrition (Benzeval et al., 2021). Furthermore, our main pattern of 
findings of which ethnic, age and gender groups were most likely to be 
vaccine hesitant was also seen in unweighted analyses (results not 
shown). Secondly, small numbers did not allow for detailed analysis of 
some ethnic groups. Additionally, we did not ask about the different 
types of vaccinations being developed and whether this would have any 
bearing on vaccine hesitancy. While we highlight associations between 
vaccine hesitancy and range of socio-demographic factors, the purpose 
of this analysis was descriptive. Willingness to be vaccinated is influ-
enced by public health and other communications, as well as a broader 
range of social factors. These associations should therefore not be 
interpreted as immutable effects but rather guide vaccination planning. 
There have been some other smaller UK studies of COVID-19 vaccine 
hesitancy which have not been based on representative samples. These 
studies indicated that 14% of participants were unwilling to receive a 
COVID-19 vaccine with a further 22% being unsure as to whether they 
would take this, with only 64% willing to take a COVID-19 vaccine. 
(Paul et al., 2021) A study conducted in Ireland and UK during the early 
phase of the pandemic found vaccine hesitancy of 35% and 31% in these 
populations respectively (Murphy et al., 2021). A non-probability online 
survey in Autumn 2020 found 71.7% were willing to be vaccinated, 
16.6% were very unsure, and 11.7% were very vaccine hesitant 
(Freeman et al., 2020). A Scottish survey found uptake figures to be 
slightly higher at between 74 and 78%. A poll by Ipsos MORI in late 
October 2020 found 67% of the UK public said they were very (42%) or 
fairly (25%) likely to take a COVID-19 vaccine (Ipsos, 2020). Our study 
suggests slightly higher vaccine uptake in the general UK population of 
82% with vaccine hesitancy at 18%. 
Given the age related focus of the Phase One vaccination roll out in 
the UK (Joint Committee on Vaccination and Immunisation, 2020), our 
study suggests that uptake is likely to be high in the target groups. 
However, the finding of greater vaccine hesitancy amongst some, but 
not all, ethnic minority groups is concerning and aligns with emerging 
evidence from other countries. This is not inevitable – studies focused on 
intention to receive vaccines prior to this pandemic have not consis-
tently found greater levels of vaccine hesitancy among ethnic minority 
groups (Bish et al., 2020; Han et al., 2016). Nevertheless, it needs to be a 
key focus of the design of vaccination programmes, given the higher 
prevalence of COVID-19 among ethnic groups and the need to avoid 
exacerbating existing inequalities (Ethnicity subgroup of the Scientific 
Advisory Group on Emergencies, 2020). Our study also found that those 
who had lower education levels were more likely to be vaccine hesitant 
Fig. 2. Proportions of vaccine hesitancy and willingness to be vaccinated (weighted proportions with 95% CI).  
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Fig. 2. (continued). 
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suggesting that there similarly needs to be added focus on increasing 
vaccine uptake with those experiencing socioeconomic disadvantage 
who are at more risk of COVID-19 (Niedzwiedz et al., 2020). 
Vaccine hesitancy rates vary by country and population subgroup. 
However, international evidence across several studies suggests that 
approximately 25% of the general population are hesitant about 
accepting a COVID-19 vaccine (Peretti-Watel et al., 2020; Detoc et al., 
2020; Grech et al., 2020; Dror et al., 2020; Ward et al., 1982; Wang et al., 
2020). A systematic review of studies on willingness to be vaccinated 
suggests 60% of people intend to be vaccinated, indicating the UK may 
be better placed to utilise vaccination to address the pandemic (Rob-
inson et al., 2020). In some countries, such as Italy, previous vaccination 
rates suggest uptake may be too low to stop the spread of COVID-19 
(Palamenghi et al., 2020). Our study suggests that this is not the case 
in the UK and if everyone who has said they are likely or very likely to 
take up the vaccination if offered, actually get vaccinated, coverage in 
the UK could be high enough to achieve herd immunity. Existing 
research for vaccine hesitancy suggests that key drivers for uptake were 
perceived efficacy of a vaccine, concern over negative adverse effects 
and safety of a vaccine (Paul et al., 2021; Dror et al., 2020; Yeung et al., 
2016). Our study also found fears over adverse effects and safety to be 
key reasons for vaccine hesitancy, especially future negative effects. 
However, our study also adds that knowing that a vaccine is effective in 
reducing the spread of COVID-19 could increase uptake. 
Fig. 3. Reasons for vaccine hesitancy, willingness to take vaccines and factors that would persuade people to take a vaccine (weighted proportions with 95% CI bars).  
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Fig. 3. (continued). 
Table 2 
Logistic regression models for vaccine hesitancy.   
Model 0 Unadjusted 
Regression 
Model 1 Age & Gender Model 2 All 
covariates1  
OR 95% CI OR 95% CI Predicted Probability2 OR 95% CI 
Gender        
Male (Ref) 1 – 1 –  15.9% 1 – 
Female 1.546 1.283, 1.863 1.539 1.275, 1.858  22.6% 1.674 1.392, 2.015 
Age        
16–24 1.479 0.995, 2.198 1.503 1.021, 2.213  22.0% 1.286 0.849, 1.948 
25–34 1.624 1.181, 2.232 1.669 1.210, 2.301  23.9% 1.643 1.162, 2.323 
35–44 1.309 0.991, 1.729 1.313 0.994, 1.735  19.8% 1.419 1.064, 1.892 
45–54 (Ref) 1 – 1 –  15.8% 1 – 
55–64 0.688 0.521, 0.907 0.692 0.525, 0.912  11.5% 0.608 0.464, 0.796 
65–74 0.362 0.239, 0.547 0.366 0.243, 0.553  6.4% 0.327 0.231, 0.464 
75+ 0.194 0.102, 0.370 0.197 0.104, 0.375  3.6% 0.171 0.084, 0.348 
Ethnicity        
White British or Irish (Ref) 1 – 1 –  10.8% 1 – 
Other white background 1.935 1.193, 3.140 1.758 1.097, 2.818  17.4% 1.651 0.963, 2.829 
Mixed 2.590 1.088, 6.168 1.735 0.801, 3.757  11.9% 2.091 0.972, 4.501 
Asian or Asian British – Indian 1.383 0.805, 2.374 1.113 0.637, 1.946  26.0% 1.175 0.617, 2.238 
Asian or Asian British – Pakistani/Bangladeshi 3.962 2.047, 7.668 2.906 1.502, 5.623  7.5% 2.544 1.189, 5.444 
Asian or Asian British – any other group 0.873 0.323, 2.359 0.667 0.238, 1.866  64.6% 0.852 0.306, 2.377 
Black or Black British 13.530 7.569, 24.185 15.034 7.619, 29.665  12.5% 13.417 6.862, 26.236 
Other Ethnic Group 1.399 0.499, 3.923 1.180 0.385, 3.611  17.6% 1.407 0.495, 4.004 
Birth Country        
Born in UK (Ref) 1 – 1 –  15.0% 1 – 
Not Born in UK 1.952 1.391, 2.739 1.733 1.193, 2.518  23.4% 0.994 0.667, 1.482 
Shielding        
No (Ref) 1 – 1 –  16.0% 1 – 
Yes 0.780 0.486, 1.253 1.146 0.711, 1.846  17.9% 1.080 0.669, 1.744 
UK Country of residence        
England (Ref) 1 – 1 –  16.4% 1 – 
Wales 1.140 0.694, 1.871 1.105 0.674, 1.811  17.8% 1.121 0.692, 1.818 
Scotland 0.603 0.438, 0.831 0.612 0.441, 0.849  10.7% 0.817 0.583, 1.143 
N Ireland 1.362 0.720, 2.576 1.248 0.640, 2.434  19.6% 1.254 0.666, 2.359 
Education level        
Degree and Higher degree (Ref) 1 – 1 –  9.3% 1 – 
A Level or equiv 1.532 1.197, 1.962 1.488 1.124, 1.968  13.3% 1.480 1.126, 1.946 
GCSE or equiv 2.153 1.664, 2.784 2.676 2.043, 3.506  21.6% 2.520 1.918, 3.312 
Other Qualification 1.395 0.906, 2.146 2.464 1.588, 3.824  20.3% 2.109 1.399, 3.178 
None 1.484 0.893, 2.466 3.362 1.950, 5.794  25.7% 3.539 2.058, 6.085 
Dependent Variable: unlikely or very unlikely binary outcome (reference category = likely or very likely). 
1Including age (5-year age bands), gender, ethnicity, country of birth, UK country of residence, education level and shielding status. 
2Based on the reference group males aged 45–54 years. 
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5. Conclusion 
Our study has important practical implications for public health 
policy. There are identifiable subgroups of the UK population who are 
more likely to be vaccine hesitant. Vaccine hesitancy is a complex 
problem (Shen, 2020) and as such a range of practical steps need to be 
undertaken to increase uptake. Firstly, the subgroups we have identified 
as being vaccine hesitant should be included in the planning and 
development of any engagement programmes. There is the potential to 
widen health inequalities without deliberate efforts to engage those 
groups who are most likely to be affected by COVID-19 and least likely to 
take up a vaccine. Initiatives to improve uptake in Black ethnic groups 
within the UK should be an urgent priority – for example, by working in 
close partnership with communities and making use of community 
champions (Woodall et al., 2013). While universal and targeted educa-
tional interventions are necessary to enable the public to understand the 
importance of vaccination and are ethically and politically acceptable, 
they are not enough to modify behaviour or increase confidence (Verger 
and Dube, 2020). Full endorsement from regulatory bodies is likely to 
increase confidence (Kreps et al., 2020), but efforts to combat misin-
formation, especially around vaccine safety, may be warranted. The rise 
in vaccine hesitancy as a result of misinformation about safety coincides 
with the rise in social media, a growing platform for the anti-vaccination 
movement (Shen, 2020; Verger and Dube, 2020). A concerted effort to 
engage with younger adults both online and through traditional 
communication channels will be needed if confidence in a vaccine is to 
be achieved and vaccine uptake is to improve in this group, subject to 
them being included in future vaccination rollout. 
Further detailed qualitative research should investigate the reasons 
for vaccine hesitancy with the subgroups identified as highly hesitant 
and approaches to overcoming them. While compulsory vaccination is 
unlikely in the UK, we have not asked about the acceptability of 
mandated vaccination for certain situations, e.g. immunisation pass-
ports or restrictions based on vaccination status. Further research would 
be required to understand whether a form of mandating vaccination 
would be acceptable to the UK population, for example only allowing 
those vaccinated to visit care homes or travel restrictions based on 
vaccination status. As vaccination programmes continue to be imple-
mented, ongoing monitoring of uptake and vaccination attitudes are 
needed. 
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Vaccine hesitant respondents were asked to state the main reason for their decision. “What is the main reason you would not take the vaccine?” 
The chart shows main vaccine hesitancy reason by ethnic group 
Please note: Where crosstabulation created cells of values < 4, categories were combined. 
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